Jane Street Group, LLC Cassava Sciences Inc Call Options Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$9.57 - $35.08 $2.97 Million - $10.9 Million	310,600 New	310,600 $9.14 Million
Q1 2022 May 17, 2022	SELL	$32.6 - $53.05 $13.2 Million - $21.4 Million	-404,000 Reduced 59.5%	275,000 $10.2 Million
Q4 2021 Feb 15, 2022	SELL	$36.77 - $90.91 $19.1 Million - $47.3 Million	-520,300 Reduced 43.38%	679,000 $29.7 Million
Q3 2021 Nov 16, 2021	BUY	$41.79 - $135.3 $33.5 Million - $108 Million	801,400 Added 201.41%	1,199,300 $74.5 Million
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $765,170 - $2.14 Million	23,800 Added 6.36%	397,900 $34 Million
Q1 2021 May 18, 2021	BUY	$7.09 - $87.95 $2.49 Million - $30.9 Million	351,100 Added 1526.52%	374,100 $16.8 Million
Q4 2020 Feb 17, 2021	SELL	$6.79 - $12.25 $1.2 Million - $2.16 Million	-176,300 Reduced 88.46%	23,000 $157,000
Q3 2020 Nov 17, 2020	BUY	$2.86 - $11.51 $569,998 - $2.29 Million	199,300 New	199,300 $2.29 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $1.05B
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.